Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Vender

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
American Journal of Clinical Dermatology|June 1, 2006
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trialStephen White, Ronald Vender, Diamant Thaçi, et al.
Journal of Cutaneous Medicine and Surgery|October 31, 2017
A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in AdultsCharles W Lynde, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 6, 2020
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus PaperJensen Yeung, Melinda J Gooderham, Parbeer Grewal, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Clinical and Experimental Rheumatology|December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeksArthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
JAAD International|August 19, 2021
Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilArnon D Cohen, Ronald Vender, Luigi Naldi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
American Journal of Clinical Dermatology|June 1, 2006
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trialStephen White, Ronald Vender, Diamant Thaçi, et al.
Journal of Cutaneous Medicine and Surgery|October 31, 2017
A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in AdultsCharles W Lynde, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 6, 2020
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus PaperJensen Yeung, Melinda J Gooderham, Parbeer Grewal, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Clinical and Experimental Rheumatology|December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeksArthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
JAAD International|August 19, 2021
Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilArnon D Cohen, Ronald Vender, Luigi Naldi, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Pageof 8